FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TEMENT	OF CHANGE	S IN RENEEICIA	I OWNEDSHI

UIVID APP	ROVAL
OMB Number:	3235-028

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Name and Address of Reporting Person*     Ocain Tim				<u>E</u>	2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [ ENTA]								ationship of Reportir k all applicable) Director Officer (give title below)		10% Ow		vner
	`	First) ARMACEUTICA REET	(Middle) ALS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 11/20/2014								Senior Vice President				
(Street)		fA	02472		4. If Amendment, Date of Original Filed (Month/Day/Year) 11/21/2014					6. Ind Line) X	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City)	(5	State) Ta	(Zip) ble I - Non-De	erivati	ve Se	curitie	s A	cauired. D	Disposed	of. or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3)			2. T Dat (Mo	ransactio e nth/Day/	2A. Deemed Execution Date, if any (Month/Day/Year)		ger) 3. Transact Code (In 8)	4. Securion Dispose 5)  Amount	ecurities Acquired (A) occurred (A) or		or and ce	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Ownership Instr. 4)	
			Table II - Der (e.g					quired, Di	•	,		•	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		ities ng re Secu	Derivative Security urity (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$44	11/20/2014		A		27,500		(1)	11/20/2024 <sup>()</sup>	Commor Stock	27,5	500	\$0	27,500	0	D	

## **Explanation of Responses:**

- 1. Such option will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2014).
- 2. This Form 4 is being amended to correct the original Form 4 filing by amending the expiration date of the granted stock option from "11/20/2014" to "11/20/2024". This amendment corrects an administrative

## Remarks:

/s/ Nathaniel S. Gardiner as 11/22/2016 attorney-in-fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.